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 Genome-wide association studies (GWAS) provide a means of examining the common genetic 
variation underlying a range of traits and disorders. In addition, it is hoped that GWAS may 
provide a means of differentiating affected from unaffected individuals. This has potential 
applications in the area of risk prediction. Current attempts to address this problem focus on 
using the polygene risk score (PRS) to predict case-control status on the basis of GWAS data. 
However this approach has so far had limited success for complex traits such as schizophrenia 
(SZ). This is essentially a classification problem. Artificial neural networks (ANNs) have been 
shown in recent years to be highly effective in such applications. Here we apply an ANN to the 
problem of distinguishing SZ patients from unaffected controls. We compare the effectiveness 
of the ANN with the PRS in classifying individuals by case-control status based only on genetic 
data from a GWAS. We use the schizophrenia dataset from the Psychiatric Genomics 
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Consortium (PGC) for this study. Our analysis indicates that the ANN is more sensitive to sample 
size than the PRS. As larger and larger sample sizes become available, we suggest that ANNs are 
a promising alternative to the PRS for classification and risk prediction for complex genetic 
disorders.  
Keywords 
Genome-wide association study, Single nucleotide polymorphism, Polygenic risk score, 
Artificial neural network, Complex genetic disorder. 
 
Background 
Genome-wide association studies (GWAS) capture common genetic variation in the form of 
single nucleotide polymorphisms (SNPs)and hence provide a means of investigating the 
genetic architecture of common heritable traits and disorders. In particular, the case-control 
GWAS, the most frequent GWAS design, has been used to identify systematic genetic 
differences between cases and unaffected controls in many complex disorders such as 
schizophrenia (SZ) [17]. One can also consider the inverse problem; that is, given the 
genetic profile of an individual, can we predict their case or control status? This has 
obvious applications in risk prediction in the clinical and public health areas even in the 
absence of a detailed understanding of the genetic mechanisms involved. But the 
classification problem is still a challenge. This is due to small effect sizes and the random 
variation of SNP allele frequencies as a result of finite sample sizes, as well as the polygenic 
nature of complex genetic disorders.  
This classification problem has been addressed (in the context of GWAS) principally 
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through the use of the polygenic risk score (PRS) ([20], [8], [10]). For a PRS analysis, each 
individual in a test dataset is assigned a PRS which summarises their risk for the disorder or 
trait in question. The PRS is calculated by summing up the number of risk alleles the 
individual possesses for each SNP weighted by its effect size obtained from an independent 
training GWAS association analysis. The SNPs are all treated as independent. Examples are 
beginning to appear of the use of the PRS in a clinical setting. For example, the PRS has shown 
potential for screening individuals for breast cancer risk [13] but its clinical utility is currently 
limited [26]. For complex disorders such as SZ, the proportion of liability explained by the PRS is 
relatively low (about 7% for SZ, [17]). Thus, the PRS on its own does not have the ability to 
discriminate effectively between affected and unaffected individuals [11]. In addition, 
standard independent testing of SNPs for association with traits is restrictive and does not 
allow for the possibility of identifying joint associations and interactions between SNPs. 
In addition, it has been suggested that, due to the large number of SNPs used in the 
analysis, that (even after correction for population stratification) a significant fraction of the 
signal detected by the PRS is actually due to residual population effects [7].  
Genetic classification can be viewed as a pattern recognition problem; a class of problems 
for which artificial neural networks (ANNs) are particularly well suited. ANNs constitute a 
specific form of machine learning. The possibility of using machine learning methods for 
classification in genetics has been considered for over a decade (see, for example [18], [21], 
[22] for some early reviews). More recently, attention has been drawn to the potential of 
deep learning, essentially a form of ANN using large numbers of hidden layers [27]. GWAS 
data present particular challenges for methods such as ANNs, in that the number of features 
(SNPS) is typically large in comparison with the number of training examples (sample size). 
Early studies (see, for example [1], [2], [3], [4], [5]), used small sample sizes (typically a few 
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hundred samples) and in fact only a few tens of SNPs, although clinical covariates were 
typically included as well. The number of SNPs (9000) used in a recent study ([6]) was 
comparable to the number used in the work we report here but the sample size was still 
small (approximately 1800). Here we exploit the large sample sizes now available to 
investigate the potential of ANNs to predict disease risk on the basis of genetic data alone 
given a sufficient number of training examples. The use of genetic data alone potentially 
allows the prediction of risk before disease onset when clinical data are not yet available. 
The specific dataset that we use is the SZ dataset from the Psychiatric Genomics Consortium 
(PGC), (containing approximately 64,000 samples), see Methods section. 
Results 
Sensitivity to Number of SNPs 
The results of our analysis are shown in Fig 1 and Table 1 where we have varied the number 
of SNPs, for different sample sizes (10,000, 30,000, and 64,542). For each sample size we show 
the show the variation in performance for different p-value thresholds. Classification 
efficiency is measured as area under the curve (AUC). The ANN performs better than the 
PRS when small numbers of SNPs are used in the analysis. However, both methods become 
comparable as the number of SNPs increases for a given sample size (see Fig 1, plots (a), (b), 
(c)). Both methods show an improvement in performance that levels off as the number of 
SNPs increases beyond a certain point. 
Sensitivity to Sample Size 
Results for our sensitivity to sample size analysis can be seen in Fig 2 and Table 2 where we 
have varied the sample size for three different numbers of SNPs. Our results indicate a 
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higher level of performance for the ANN relative to the PRS in Fig 2, plots (a) and (b). This 
difference in performance increases with increasing sample size. In Fig 2, plot (c) the ANN 
performs less well for lower sample sizes (10,000, 20,000, and 30,000). For larger sample sizes 
it outperforms the PRS. 
Discussion 
We have carried out analyses on the performance of an ANN and the PRS in classifying case- 
control status using GWAS schizophrenia data. We conducted sensitivity analyses with respect 
to both number of SNPs and sample size. Before discussing the results, we briefly review 
the differences between these two approaches to classification. In the PRS approach, an 
individual in a test dataset is assigned case or control status according to their risk score. The 
score is calculated by summing the number of risk alleles the individual possesses for each 
SNP weighted by its effect size. This effect size is obtained from an independent (training) 
dataset. The SNPs are treated as independent and the score is refined by increasing the 
number of SNPs in the analysis. The precision with which the effect size is estimated is 
improved by increasing the sample size in the training dataset. In the ANN, on the other 
hand, all SNPs are simultaneously taken into account for each sample. The network weights 
are adjusted accordingly, using the data from the training set and these weights are used 
to calculate probabilities of class membership in a test dataset. The probabilities are refined 
by increasing the sample size in the training dataset. 
These two approaches are therefore complementary, and while we would expect the 
performance of both to increase with both sample size and number of SNPs, the behaviour of 
the two methods as these parameters vary will, in general, differ.  
In our sensitivity to number of SNPs analysis (Fig 1, Table 1) the ANN initially performs better 
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than the PRS. However, the PRS improves more quickly as the number of SNPs increases for a 
given sample size (see Fig 1, plots (a), (b), (c)). In both cases, the rate of improvement slows as 
the number of SNPs increases beyond a certain point. We have restricted the analysis to p-
value thresholds less than 0.05 (corresponding to approximately 16,000 SNPs for the largest 
sample size). This is partly for practical reasons (computation time for the ANN). It is also 
desirable to keep the number of features reasonably small compared to the number of training 
examples. It is possible that a further improvement in performance may result if the number 
of SNPs is greatly increased. Our objective here is not to achieve the maximum possible 
performance but to compare the behaviour of the two methods as the number of SNPs is 
varied. Performance, on the other hand, does improve as the sample size is increased (for 
example, at a p-value threshold of 0.05 with overall sample size of 10,000, mean (se) ANN 
AUC = 0.578 (0.006), mean (se) PRS AUC = 0.584 (0.005), mean (sd) number of SNPs = 9,681 
(124), with overall sample size 30,000, mean (se) ANN AUC = 0.617 (0.004), mean (se) PRS AUC 
= 0.628 (0.004), mean (sd) number of SNPs = 12,184 (109), and with overall sample size of 
64,542, mean (se) ANN AUC = 0.661 (0.002), mean (se) PRS AUC = 0.669 (0.002), mean (sd) 
number of SNPs = 16,054 (154), see Fig 1, plots (a), (b), (c) and Table 1). 
Note that the same p-value threshold at the larger sample sizes (for example, Fig 1, plot (c) 
in comparison to Fig 1 plot (a)) implies an increase in the number of SNPs available for 
analysis. This means that we cannot make a definitive statement about the behavior of the 
methods as sample size increases on the basis of the SNP sensitivity analysis above. This issue 
is addressed explicitly in our second sensitivity analysis where the number of SNPs is kept 
approximately constant as we vary the sample size.  
Results for our sensitivity to sample size analysis can be seen in Fig 2 and Table 2 where we 
have varied the sample size for three different sets of SNPs obtained from different p-value 
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thresholds in a reference dataset. The maximum threshold used was 0.015 corresponding to 
approximately 3500 SNPs. The reason for this restriction was computation time for the ANN. It 
is likely that performance will improve further if a larger number of SNPs is used, however 
our objective here was to compare the behaviour of the two methods as sample size is varied, 
rather than to achieve optimum performance. Our results indicate a higher level of 
performance for the ANN relative to the PRS in Fig 2, plot (a) with 661 SNPs (mean) and 
plot (b) with 1,377 SNPs (mean). This difference in performance increases with increasing 
sample size. In Fig 2, plot (c), with 3,531 SNPs (mean), the ANN performs more poorly for 
lower sample sizes (10,000, 20,000, and 30,000). For larger sample sizes it begins to 
outperform the PRS. 
 
Conclusions 
there are two basic parameters that we can consider when we are carrying out this type of 
analysis: the number of SNPs and the sample size. We find that the performance of the PRS 
is more sensitive to the number of SNPS, while the ANN is more sensitive to the sample size. 
We emphasize that the ANN architecture used here has been minimal (one hidden layer, two 
hidden nodes). In particular, the architecture has not been specifically optimised for this 
dataset and our results therefore have general validity. There is considerable scope for further 
development with regard to the optimisation of the architecture in order to further improve 
the ANN’s performance on this dataset.  
Performance in terms of computation time has also not been optimised (see Supporting 
Information (SI) for details) since we do not regard this as a critical issue at this stage of 
development. Training times are therefore relatively long, in contrast to the PRS which 
requires only an association analysis on the training dataset to obtain the odds ratios 
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required to compute the scores.  Significant reductions in computation time should be 
achievable by optimisation of for example, step-size and (in particular) parallelisation. 
An important issue for ANNs (and machine learning methods in general) is the dissemination 
of the results. (This is straightforward in the case of the PRS, since all that is required is the 
list of SNPs used and the associated odds ratios.) All the information for the trained 
network is available, in principle, in the list of SNPs and the list of network weights and 
biases; however this information is difficult to use and interpret in practice and it is desirable 
to have a complete end-to-end pipeline available. This is beyond the scope of the present 
work, but we plan to develop such a pipeline in the next phase of this project. 
In summary, we have presented here an alternative potential approach to the current 
method of choice, the PRS for case-control classification. Our analysis indicates that the 
ANN outperforms the PRS at large sample sizes and will therefore prove a promising 
alternative to the PRS for the very large sample sizes that are now becoming available. 
The results we have presented here are a proof-of-concept. Our ANN requires further 
optimisation to maximise performance. The system will also require further optimisation 
for speed in order to handle larger numbers of SNPs. In addition, a fully developed pipeline 
will be required in order for the system to be easily useable by the wide community. These 
issues will be addressed in the next phase of this work. 
 
Methods 
Data 
We use the PGC SZ data (Ripke et al. [17]). Of the total of 43 datasets analysed in [17] we 
have been granted access to 40, representing 84.1% of the total case-control data originally 
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analysed (67,184 of 79,845 samples), (86.7% of the cases (29,689 of 34,241), 82.2% of the 
controls (37,495 of 45,604)). Each of these datasets has been imputed using the 1000 
Genomes Project reference panel [19] and quality control (QC) has been applied to these 
individual datasets prior to our accessing the data. We use the datasets that have been 
subjected to a light QC (best guess genotypes based on imputation, SNP missing rate <2%) in 
order to maximise the overlap of SNPs between the datasets as we are performing a mega 
analysis rather than a meta-analysis. These datasets have approximately 7,000,000 variants 
each, see SI Table S1. These data have been made available by the PGC, see 
Acknowledgements for details of how to access these data. 
 
Data Quality Control, Filtering and Principal Component Analysis 
We merged all 40 datasets using the PLINK 1.9 software [14] command -merge-list. This 
resulted in a dataset consisting of approximately 14,000,000 variants and 67,184 samples 
(29,689 cases, 37,495 controls). Next, non-SNP variants were removed, SNP missingness 
(>0.01) and individual missingness (>0.02) filtering was carried out, and related samples were 
removed (random removal of one individual from pairs of related samples with cases 
preferentially retained). Additional SNP QC was then carried out. This resulted in what we 
refer to as the Mega dataset consisting of approximately 2,000,000 variants (not all imputed 
SNPs were present in all 40 datasets). The dataset consisted of 64,542 samples (28,707 cases, 
35,835 controls), see Table 3. This Mega dataset was used as the basis for all subsequent 
analyses. In addition to filtering steps for SNPs and samples being carried out as part of the 
QC it was necessary to conduct principal component analyses (PCAs) in order to adjust 
association analyses for population stratification that is present in this merged dataset. For a 
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PCA the dataset was pruned using Plink 1.9 [14] (indep-pairwise 50 5 0.1) and regions of 
known long-range high linkage disequilibrium (LD) were removed [16]. The PCA analysis was 
then carried out using the software SmartPCA [15] on the resulting pruned dataset. 
 
Association Findings for Mega Datasets 
As we are conducting a mega analysis here and Ripke et al. [17] conducted a meta-analysis 
we carried out a comparison of top significant results between the two approaches for 
reference. We conducted an association analysis on the Mega dataset, including the first 10 
PCs. Ripke et al. identified 128 LD independent SNPs that exceeded genome-wide 
significance (p-value 5x10e−8). For each of these 128 top hits, an associated locus was 
defined as the physical region containing SNPs correlated at r2 > 0.6 with each of the 128 
index SNPs. Of these 128 top hit regions, 111 are associations on chromosomes 1 to 22 (we 
are not considering sex chromosomes here) and are bi-allelic SNPs, the other 17 are either 
on the sex chromosomes (3 on chrX) and/or are not bi-allelic SNPs (14 indels). For each of 
these 111 regions we identified whether or not we had a SNP included in these regions in 
our Mega dataset, resulting in 95 SNP regions that overlap with Ripke et al. [17] (86%). Of 
these 95 overlapping regions, we identified 39 (41%) that contained a SNP in our analysis 
that also had a p-value ≤ 5x10e−8  in our mega association analysis. See Figs S1-S4 in SI for 
further details. Broadly speaking our results are consistent with those of Ripke et al. [17]. 
 
Artificial Neural Networks 
In this section we briefly review the principles of artificial neural networks, as used for 
classification. An ANN consists of a number of interconnected neurons, or nodes, each of 
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which processes information and passes it to other nodes in the network. There is an input 
layer which receives its inputs from the user and an output layer which delivers the outputs. In 
general, there will be one or more intermediate hidden layers; this is the architecture of the 
network (see Fig 3). In the course of training, both inputs and outputs are specified and the 
ANN adjusts the network weights in order to achieve the best fit to the data. In this way 
the ANN learns to recognise patterns. In our application, the inputs are the SNP genotypes 
for each individual. There is a single output node - the probability of the case or control 
status of each individual. 
The complexity of the behaviour of the ANN increases with the number of hidden nodes and 
hidden layers. Since in this study we are primarily interested in the general question of the 
performance of the ANN on large genetic datasets (and not on optimisation with respect to a 
particular disorder), we used a simple architecture with a single hidden layer consisting of 
two hidden nodes. The network is trained on a subset of the cases and controls. After 
training, the network is tested on an independent subset to assess its accuracy in predicting 
case/control status. We use the Skynet ANN for all analyses [9]. See SI for further details on 
the computational performance of this ANN. 
 
Analysis Plan 
All supervised learning classification problems incorporate two distinct steps. The first step, 
feature selection, involves determining the inputs that will be used to compute the 
classification. The second step, training, involves allocating appropriate weights to the 
selected features by using a training dataset in which both features and class labels are 
supplied. The trained classifier then uses these weights to classify new, previously unseen 
instances. 
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We begin by splitting the data into two non-overlapping subsets: training and test. The 
majority of the data (approximately 90%) is allocated to the training dataset. We perform 
additional SNP QC filtering (see Part 2, Table 3) independently on the training and test 
datasets. We conduct a PCA on the training dataset. We then carry out an association 
analysis correcting for PCs on the training dataset. We select SNPs (based on the 
association analysis and LD clumping in order to determine independent signals). These 
SNPs are the features for the classification step. For classification via the PRS the odds 
ratios (ORs) from the association analysis on the training dataset are supplied, as well as 
the SNP genotypes of the test dataset. We use the R statistical package PRSice [23] to 
compute the PRS. For classification in the ANN, the full genotype information for the 
selected SNPs for both the training and test datasets is required but not the ORs. This is the 
main difference in the information that is supplied to these classification methods. Based on 
the information that has been provided for the PRS a score is calculated for each sample in 
the test dataset which consists of the genotype data for the selected SNPs. In the case of the 
ANN the training genotypes are used to compute the network weights using the training 
data. These weights are then used to calculate class membership probabilities for each of the 
samples in the test dataset. See Figs S5-S8 in SI for details on the workflow. In order to 
examine the stability of the methods and to get error bounds we created ten independent 
training and test datasets as follows. We split the dataset into ten random disjoint subsets. 
Each of these ten is used as a test dataset with its corresponding training dataset consisting 
of the other nine datasets combined. This ensures that all test datasets are independent of 
each other and each is independent of their associated training dataset. 
 
Comparison of Performance 
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A standard method for assessing the performance of a classifier is the AUC and we employ this 
here. All AUCs are calculated in R [24] using the package pROC [25]. 
 
Sensitivity to number of SNPs 
The aim here is to compare the performance of both methods as we vary the number of 
SNPs. We examine the performance for three different sample sizes. We randomly select 
10,000 (30,000 or use all of the Mega dataset) samples from the Mega dataset. We then 
split this dataset into ten disjoint subsets as described above. Each of these ten subsets is 
considered in turn as a test dataset with the remaining subsets its corresponding training 
dataset. This gives us ten replicates and enables us to compute a standard error (se) on the 
results. The ten test datasets are independent of each other by construction and each test 
dataset is also independent of its corresponding training dataset. For each replicate we 
carry out QC on the test and training dataset independently as described above. We then 
conduct an association analysis on the training dataset to obtain p-values for the SNPs. We 
then use these p-values to clump the SNPs at different levels of significance with results 
grouped based on LD (–clump command in plink). This ensures independence of the SNPs. 
As the significance level increases the number of SNPs yielded also increases allowing us to 
examine the behavior of the methods as we vary the number of SNPs. 
 
Sensitivity to Sample Size 
The aim here is to compare the performance of both methods as we vary the number of 
samples. We examine the performance for three different p-value thresholds. In order to 
maintain approximately the same number of SNPs as we vary the sample size it is necessary to 
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generate a reference set of SNPs from an independent subset of the Mega dataset. We 
randomly select 10,000 samples from the Mega dataset. We then conduct QC and PCA and 
an association analysis on this subset of data. We obtain three reference lists of SNPs at p-
value thresholds: 0.002, 0.005, and 0.015 and the resulting SNPs are also clumped to 
ensure independence of signals. These yield SNP sets of size 677, 1,411, and 3,608, 
respectively. We then use the remaining 54,542 samples of the Mega dataset to create ten 
disjoint subsets as described previous section. For each replicate we carry out QC on the test 
and training dataset independently as described above. We then conduct an association 
analysis on the training dataset. This provides the ORs necessary for the PRS. The SNPs to be 
used in the analysis are selected from the reference list. Note that not all SNPs in the 
reference list will be present due to QC, particularly at lower sample sizes, but these 
variations are small, see Table 2. This allows us to examine the behavior of the methods as 
we vary the sample size using an approximately fixed number of SNPs. 
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 P-value 
threshold 
SNPs  
Mean (sd) 
Reps ANN  
Mean (se) 
PRS  
Mean (se) 
 
Sample Size       
10,000 0.001 368 (19) 10 0.554 (0.004) 0.549 (0.007)  
 0.005 1378 (29) 10 0.572 (0.006) 0.570 (0.006)  
 0.010 2481 (35) 10 0.584 (0.007) 0.576 (0.005)  
 0.015 3481 (53) 10 0.578 (0.006) 0.579 (0.004)  
 0.020 4439 (63) 10 0.583 (0.006) 0.581 (0.005)  
 0.035 7123 (69) 10 0.586 (0.005) 0.583 (0.005)  
 0.050 9681 (124) 10 0.578 (0.006) 0.584 (0.005)  
Sample Size       
30,000 0.001 770 (29) 10 0.599 (0.002) 0.578 (0.003)  
 0.005 2253 (42) 10 0.611 (0.003) 0.599 (0.004)  
 0.010 3686 (46) 10 0.617 (0.003) 0.610 (0.004)  
 0.015 4936 (63) 10 0.616 (0.004) 0.615 (0.004)  
 0.020 6100 (70) 10 0.617 (0.002) 0.618 (0.004)  
 0.035 9286 (106) 10 0.616 (0.004) 0.623 (0.003)  
 0.050 12184 (109) 10 0.617 (0.004) 0.628 (0.004)  
Sample Size       
64,542 0.001 1727 (20) 10 0.653 (0.001) 0.625 (0.002)  
 0.005 3985 (35) 10 0.661 (0.002) 0.645 (0.002)  
 0.010 5914 (87) 10 0.661 (0.002) 0.652 (0.002)  
 0.015 7536 (108) 10 0.658 (0.002) 0.655 (0.002)  
 0.020 8979 (117) 10 0.661 (0.002) 0.659 (0.002)  
 0.035 12764 (146) 10 0.659 (0.002) 0.665 (0.002)  
 0.050 16054 (154) 10 0.661 (0.002) 0.669 (0.002)  
 
Table 1: Sensitivity to Number of SNPs. The results presented in this table are also to be found 
in Fig 1. 
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 Sample 
Size 
SNPs 
Mean (sd) 
Reps ANN  
Mean (se) 
PRS  
Mean (se) 
 
P-value threshold 0.002       
~661 SNPs 10000 652 (5) 10 0.541 (0.004) 0.533 (0.007)  
 20000 655 (4) 10 0.564 (0.004) 0.552 (0.004)  
 30000 663 (4) 10 0.576 (0.004) 0.559 (0.004)  
 40000 667 (3) 10 0.575 (0.008) 0.563 (0.003)  
 50000 665 (3) 10 0.580 (0.002) 0.561 (0.003)  
 54542 665 (3) 10 0.583 (0.003) 0.563 (0.002)  
P-value threshold 0.005       
~1,377 SNPs 10000 1333 (9) 10 0.552 (0.007) 0.545 (0.005)  
 20000 1366 (9) 10 0.563 (0.005) 0.557 (0.004)  
 30000 1381 (8) 10 0.578 (0.003) 0.565 (0.003)  
 40000 1388 (5) 10 0.586 (0.003) 0.571 (0.003)  
 50000 1386 (6) 10 0.588 (0.002) 0.569 (0.003)  
 54542 1386 (7) 10 0.589 (0.003) 0.571 (0.002)  
P-value threshold 0.015       
~3,531 SNPs 10000 3469 (24) 10 0.546 (0.011) 0.553 (0.005)  
 20000 3508 (15) 10 0.558 (0.003) 0.568 (0.004)  
 30000 3539 (18) 10 0.572 (0.003) 0.578 (0.003)  
 40000 3557 (11) 10 0.586 (0.002) 0.581 (0.002)  
 50000 3554 (13) 10 0.589 (0.004) 0.585 (0.003)  
 54542 3557 (11) 10 0.595 (0.003) 0.584 (0.002)  
 
Table 2: Sensitivity to Sample Size. The results presented in this table are also to be found in 
Fig 2. 
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 SNPs Cases Controls Samples 
Merged Datasets     
 13,802,094 29,689 37,495 67,184 
PART 1                                          SNP QC     
SNPs only, no indels, --snps-only -865,628 - - - 
SNP call rate < 0.99, --geno 0.01 -10,917525 - - - 
     
Individual QC     
Individual call rate < 0.98, --mind 0.02 - -216 -193 -409 
*Relatedness PI-HAT > 0.2, --genome - -766 -1,467 -2,233 
     
Remaining 2,018,941 28,707 35,835 64,542 
     
PART 2                                          SNP QC     
SNP call rate < 0.99, --genp 0.01 -3,650 - - - 
Diff missing cases and controls > 0.02 0 - - - 
HWE – controls <= 10e-6 -5,815 - -  - 
HWE – cases <= 10e-10 -16 - - - 
MAF < 0.01 -2,912 -  - - 
     
Mega Dataset                      Remaining 2,006,548 28,707 35,835 64,542 
 
Table 3: Quality Control. Part 1 and Part 2 QC filters applied to the 40 merged datasets. 
Part 2 filters are applied to the training and test datasets. *Analysis is conducted on 
a pruned dataset, same pruning applied as for PCA analysis. Pairs of related samples with a 
PI-HAT > 0.2 are identified and one individual is removed from the pair with cases 
preferentially retained. Analysis is repeated on remaining samples to again check for 
relatedness. 
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Figure 1: Sensitivity to Number of SNPs. The results presented in this figure are also to be 
found in Table 1. 
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Figure 2: Sensitivity to Sample Size. The results presented in this figure are also to be 
found in Table 2. 
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Figure 3: Artificial Neural Network Architect
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 Dataset Cases Controls Samples .bg Variants 
1 scz cims eur-qc 71 69 140 7,176,582 
2 scz zhh1 eur-qc 191 190 381 5,204,976 
3 scz pews eur-qc 150 236 386 7,292,337 
4 scz lie2 eur-qc 137 269 406 7,886,295 
5 scz swe1 eur-qc 221 214 435 6,047,632 
6 scz msaf eur-qc 327 139 466 7,955,321 
7 scz port eur-qc 346 216 562 6,408,457 
8 scz lacw eur-qc 157 466 623 7,549,844 
9 scz edin eur-qc 368 284 652 7,484,683 
10 scz ersw eur-qc 322 332 654 8,132,615 
11 scz caws eur-qc 424 306 730 6,122,240 
12 scz top8 eur-qc 377 403 780 7,451,253 
13 scz munc eur-qc 437 351 788 6,508,392 
14 scz cati eur-qc 409 392 801 6,612,133 
15 scz buls eur-qc 195 608 803 7,340,965 
16 scz asrb eur-qc 509 310 819 7,651,487 
17 scz lie5 eur-qc 509 389 898 7,506,231 
18 scz umes eur-qc 197 713 910 7,709,209 
19 scz denm eur-qc 492 458 950 7,643,941 
20 scz umeb eur-qc 375 584 959 8,130,401 
21 scz uclo eur-qc 521 494 1,015 5,670,555 
22 scz 3m eur-qc 186 930 1,116 7,121,806 
23 scz dubl eur-qc 272 860 1,132 7,398,573 
24 scz cou3 eur-qc 540 693 1,233 7,781,847 
25 scz ucla eur-qc 705 637 1,342 7,642,714 
26 scz egcu eur-qc 239 1,177 1,416 7,978,592 
27 scz aber eur-qc 720 699 1,419 6,214,060 
28 scz i6 eur-qc 361 1,082 1,443 7,933,222 
29 scz aarh eur-qc 883 873 1,756 7,809,181 
30 scz swe6 eur-qc 1,094 1,219 2,313 8,129,242 
31 scz gras eur-qc 1,086 1,232 2,318 7,770,108 
32 scz irwt eur-qc 1,309 1,022 2,331 7,521,232 
33 scz ajsz eur-qc 896 1,595 2,491 7,794,461 
34 scz pewb eur-qc 641 1,892 2,533 7,425,737 
35 scz boco eur-qc 1,847 2,170 4,017 7,408,363 
36 scz clo3 eur-qc 2,150 2083 4,233 7,961,221 
37 scz s234 eur-qc 2,077 2,341 4,418 7,771,960 
38 scz swe5 eur-qc 1,801 2,617 4,418 8,061,512 
39 scz mgs2 eur-qc 2,681 2,653 5,334 7,543,555 
40 scz clm2 eur-qc 3,466 4,297 7,763 7,419,981 
 Total Included* 29,595 36,205 67,184  
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Table S1: PGC Datasets Included in Analysis. *Datasets not available for inclusion in this analysis that were 
analysed originally in Ripke et al. 2014 [1]: scz jr (includes Johnson and Johnson and Roche cases), scz lktu eu, 
and scz pa eur. .bg stands for best guess. 
 
 
Figure S1: PC1 vs PC2 for Mega Dataset  
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Figure S2: PC1 vs PC3 for Mega Dataset  
 
 
 
Figure S3: Comparison with Ripke et al. 2014. Comparison of Ripke et al 2014 [1] meta analysis results with 
mega analysis results here for the Mega dataset.  
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Figure S4: Mega dataset association analysis results.  
Computation 
All calculations using the PGC data were carried out on the Lisa cluster which is 
part of the Dutch national e-infrastructure, where a repository of the data is 
maintained. 
Computations were performed on the E5-2650 v2 nodes, each of which has 870Gb 
of scratch space, 64 Gb of memory, 20Mb of cache and clock speed 2.6 GHz. Each 
node supports 16 cores and up to 15 computations can be run simultaneously on 
each node. In practice, due to memory requirements at various points in the 
pipeline only one run at a time was carried out on a given node. 
 
Approximate computation times on this hardware for the ANN (in serial mode) 
were as follows: 
At the lower end of the analyses described (sample size approximately 10,000, 
number of SNPs approximately 1,300), run time was approximately 28 minutes, 
standard deviation 10 minutes as measured over 10 runs. At the upper end (sample 
size approximately 54,000, number of SNPs approximately 16,000) run time was 
approximately 3,530 minutes, standard deviation 620 minutes as measured over 
10 runs. 
Computation time was observed to vary approximately linearly with both sample 
size and number of SNPs over the range considered. 
 
 
Workflow 
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Figure S5: Overall workflow for all analyses  
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Figure S6: Workflow for SNP sensitivity analysis  
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Figure S7: Workflow for Sample Sensitivity Analysis: Creating SNP sets and train and test datasets to be 
prepared for the ANN and PRS 
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Figure S8: Workflow for Sample Sensitivity Analysis: Creating train and test datasets for the ANN and PRS 
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